{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:22:20Z","timestamp":1769170940873,"version":"3.49.0"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T00:00:00Z","timestamp":1232668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mount Sinai J Medicine"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pulmonary fibrosis is an unusual \u201cend stage\u201d in patients with sarcoidosis. Fibrosis occurs in a minority of patients, and presents with a unique physiologic combination of airways dysfunction (obstruction) superimposed on the more common restrictive dysfunction. Imagin techniques are essential to the diagnosis, assessment and treatment of pulmonary fibrosis. Standard chest radiographs and CT scans may reveal streaks, bullae, cephalad retraction of the hilar areas, deviation of the trachea and tented diaphragm. Positive gallium and PET scans indicate residual reversible granulomatous disease and are important guides to therapy decisions. Treatment, usually with corticosteroids, is effective in those patients with positive scans, but fibrosis does not improve with any treatment. With severe functional impariment and patient disability, pulmonary hypertension and right heart failure may supervene for which the patient will require treatment. Oxygen, careful diuresis, sildenafil and bosentan may be salutary. These patients are candidates for lung transplantation. Mt Sinai J Med 76:30\u201336, \u00a9 2009 Mount Sinai School of Medicine<\/jats:p>","DOI":"10.1002\/msj.20090","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T20:59:17Z","timestamp":1232744357000},"page":"30-36","source":"Crossref","is-referenced-by-count":28,"title":["\u201cEnd\u2010stage\u201d Pulmonary Fibrosis in Sarcoidosis"],"prefix":"10.1002","volume":"76","author":[{"given":"Alvin T.","family":"Teirstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S.","family":"Morgenthau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,23]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)33069-3"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5261.1165"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-970336"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.10.2104046"},{"key":"e_1_2_1_6_2","first-page":"204","article-title":"Two year prognosis of sarcoidosis: the ACCESS experience","volume":"20","author":"Judson MA","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-195202000-00001"},{"key":"e_1_2_1_8_2","first-page":"405","article-title":"Sarcoidosis: from the pathologist's vantage point","volume":"14","author":"Rosen Y","year":"1979","journal-title":"Pathol Annu"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2003.01718.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200512-1839OC"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.6.1584"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.6.4255"},{"key":"e_1_2_1_13_2","article-title":"Alveolar oxidative stress is associated with elevated levels of non\u2010enzymatic low\u2010molecular\u2010weight antioxidants in patients with different forms of chronic fibrosing interstitial lung diseases","author":"Markart P","year":"2008","journal-title":"Antioxid Redox Signal"},{"key":"e_1_2_1_14_2","first-page":"S63","article-title":"Cytokine phenotypes serve as a paradigms for experimental immune\u2010mediated lung diseases and remodeling","volume":"29","author":"Kunkel SL","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"e_1_2_1_15_2","first-page":"S37","article-title":"Pulmonary fibrosis of sarcoidosis: new approaches, old ideas","volume":"29","author":"Moller DR.","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2006.00933.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200501-142OC"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000086335"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-003-1028-8"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1976.tb47040.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.152.6.1179"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.50.12.1264"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/crad.1999.0366"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.174.6.1741751"},{"key":"e_1_2_1_25_2","first-page":"CD001114","article-title":"Corticosteroids for pulmonary sarcoidosis","volume":"18","author":"Paramothayan NS","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3300"},{"key":"e_1_2_1_27_2","first-page":"45","article-title":"Value of biochemical markers in serum for determination of disease activity in sarcoidosis","volume":"1","author":"Selroos O.","year":"1984","journal-title":"Sarcoidosis"},{"key":"e_1_2_1_28_2","first-page":"329","article-title":"Serum angiotensin\u2010converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis","volume":"120","author":"Lieberman J","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-1-73"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-42375"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1178"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.3.1483"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000089815"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.1.233"}],"container-title":["Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmsj.20090","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/msj.20090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T16:47:27Z","timestamp":1699894047000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/msj.20090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1002\/msj.20090"],"URL":"https:\/\/doi.org\/10.1002\/msj.20090","archive":["Portico"],"relation":{},"ISSN":["0027-2507","1931-7581"],"issn-type":[{"value":"0027-2507","type":"print"},{"value":"1931-7581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,23]]}}}